Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Will Become Strategic Imperative For Pharmaceutical Companies, Quintiles Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pipeline pressures will make Asia a contributor to drug discovery and research innovation as well as a market and support powerhouse, the CRO says.

You may also be interested in...



Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand, IMS Study Says

Drug makers need to more aggressively target so-called "pharmerging" markets - but not just the usual suspects. Brazil, Russia, India and China remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent last year

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says

Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel